The aim of the joint research project of Andreas Meisel (Charité - Universitätsmedizin Berlin) and Hermona Soreq (Hebrew University of Jerusalem) is to better understand the body's molecular processes during a stroke and to generate new therapeutic approaches. The circulatory disorder in the brain leads to severe damage in one third of the stroke patients, which permanently affects their quality of life. Almost a third of the patients die within the first year. The brain damage causes a two-part immune reaction, which manifests itself in an inflammation of the central nervous system with simultaneous weakening of the immune system. The consequence of this autoimmune reaction are serious infections. The physicians are investigating how so-called "microRNAs", this means special ribonucleic acids, control the signal transduction of the messenger acetylcholine in the brain, which regulates the described immune reaction.
Funding period: 01/2019 - 12/2021
Contact:
Prof. Dr. med. Andreas Meisel
Charité – Universitätsmedizin Berlin
Leiter im NeuroCure Clinical Research Center (NCRC)
Charitéplatz 1
10117 Berlin
Applicant: Charité - Universitätsmedizin Berlin
Cooperation partner: Hebrew University
